WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EXEL

Based on 16 analysts offering 12 month price targets for Exelixis Inc

Min Forecast
$30.00-35.12%
Avg Forecast
$44.94-2.82%
Max Forecast
$51.00+10.29%

Should I buy or sell EXEL stock?

Based on 16 analysts offering ratings for Exelixis Inc.

Buy
Strong Buy
6 analysts 37.5%
Buy
3 analysts 18.75%
Hold
7 analysts 43.75%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their EXEL stock forecasts and price targets.

EXEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-05
lockedlocked$00.00+00.00%2025-11-05
lockedlocked$00.00+00.00%2025-11-05
lockedlocked$00.00+00.00%2025-11-05
RBC Capital
Top 7%
94
HoldReiterates$45.00-2.68%2025-10-21
Wells Fargo
Top 3%
98
HoldMaintains$30.00-35.12%2025-10-21
Leerink Partners
Top 33%
68
BuyUpgrades$48.00+3.81%2025-10-21
Goldman Sachs
Top 32%
69
Strong BuyInitiates Coverage On$47.00+1.64%2025-09-17
Truist Securities
Bottom 6%
6
Strong BuyMaintains$49.00+5.97%2025-07-29

1 of 2

Forecast return on equity

Is EXEL forecast to generate an efficient return?

Company
58.25%
Industry
250.86%
Market
228.7%
EXEL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EXEL forecast to generate an efficient return on assets?

Company
44.57%
Industry
90.06%
EXEL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EXEL earnings per share forecast

What is EXEL's earnings per share in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$2.68+8.98%
Avg 2 year Forecast
$3.16+28.44%
Avg 3 year Forecast
$4.06+65.13%
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

EXEL revenue forecast

What is EXEL's revenue in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$2.4B+4.05%
Avg 2 year Forecast
$2.7B+16.55%
Avg 3 year Forecast
$3.1B+33.38%
EXEL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EXEL earnings growth forecast

How is EXEL forecast to perform vs Biotechnology companies and vs the US market?

Company
17.39%
Industry
43.47%
Market
42.48%
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

EXEL revenue growth forecast

How is EXEL forecast to perform vs Biotechnology companies and vs the US market?

Company
9.85%
Industry
97.96%
Market
25.83%
EXEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EXEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EXEL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EXEL$46.24$44.94-2.82%Buy
MRNA$31.20$30.30-2.88%Hold
ASND$208.98$260.64+24.72%Strong Buy
IONS$79.93$84.91+6.22%Strong Buy
BMRN$59.95$86.91+44.97%Strong Buy
View Top Biotech Stocks

Exelixis Stock Forecast FAQ

Is Exelixis Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: EXEL) stock is to Buy EXEL stock.

Out of 16 analysts, 6 (37.5%) are recommending EXEL as a Strong Buy, 3 (18.75%) are recommending EXEL as a Buy, 7 (43.75%) are recommending EXEL as a Hold, 0 (0%) are recommending EXEL as a Sell, and 0 (0%) are recommending EXEL as a Strong Sell.

If you're new to stock investing, here's how to buy Exelixis stock.

What is EXEL's earnings growth forecast for 2025-2027?

(NASDAQ: EXEL) Exelixis's forecast annual earnings growth rate of 17.39% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.

Exelixis's earnings in 2025 is $677,903,000.On average, 23 Wall Street analysts forecast EXEL's earnings for 2025 to be $718,781,882, with the lowest EXEL earnings forecast at $648,992,287, and the highest EXEL earnings forecast at $793,880,097. On average, 23 Wall Street analysts forecast EXEL's earnings for 2026 to be $847,127,171, with the lowest EXEL earnings forecast at $564,912,315, and the highest EXEL earnings forecast at $1,089,473,750.

In 2027, EXEL is forecast to generate $1,089,098,393 in earnings, with the lowest earnings forecast at $648,992,287 and the highest earnings forecast at $1,674,762,589.

What is EXEL's revenue growth forecast for 2025-2027?

(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 9.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.

Exelixis's revenue in 2025 is $2,288,218,000.On average, 22 Wall Street analysts forecast EXEL's revenue for 2025 to be $638,375,045,817, with the lowest EXEL revenue forecast at $604,324,801,878, and the highest EXEL revenue forecast at $662,237,027,790. On average, 22 Wall Street analysts forecast EXEL's revenue for 2026 to be $715,055,122,719, with the lowest EXEL revenue forecast at $641,860,503,858, and the highest EXEL revenue forecast at $834,365,032,584.

In 2027, EXEL is forecast to generate $818,278,303,164 in revenue, with the lowest revenue forecast at $631,404,129,735 and the highest revenue forecast at $1,003,543,803,651.

What is EXEL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EXEL) forecast ROA is 44.57%, which is lower than the forecast US Biotechnology industry average of 90.06%.

What is EXEL's Price Target?

According to 16 Wall Street analysts that have issued a 1 year EXEL price target, the average EXEL price target is $44.94, with the highest EXEL stock price forecast at $51.00 and the lowest EXEL stock price forecast at $30.00.

On average, Wall Street analysts predict that Exelixis's share price could fall to $44.94 by Nov 6, 2026. The average Exelixis stock price prediction forecasts a potential downside of 2.82% from the current EXEL share price of $46.24.

What is EXEL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EXEL) Exelixis's current Earnings Per Share (EPS) is $2.46. On average, analysts forecast that EXEL's EPS will be $2.68 for 2025, with the lowest EPS forecast at $2.42, and the highest EPS forecast at $2.96. On average, analysts forecast that EXEL's EPS will be $3.16 for 2026, with the lowest EPS forecast at $2.11, and the highest EPS forecast at $4.06. In 2027, EXEL's EPS is forecast to hit $4.06 (min: $2.42, max: $6.25).

What is EXEL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EXEL) forecast ROE is 58.25%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.